China
联系人 lansky
nanhu road, Wuhan, Hubei
Pirfenidone (INN, BAN) is a drug developed by several companies
worldwide, including InterMune Inc. (now part of Roche), Shionogi
Ltd., and GNI Group Ltd., for the treatment of idiopathic pulmonary
fibrosis (IPF). In ***8, it was first approved in Japan for the
treatment of IPF after clinical trials, under the trade name of
Pirespa by Shionogi & Co. In October ***0, the Indian Company
Cipla launched it as Pirfenex. In ***1, it was approved for use in
Europe for IPF under the trade name Esbriet,[2] and was approved in
the United States in October ***4 under the same name. In September
***1, the Chinese State Food and Drug Administration provided GNI
Group Ltd with new drug approval of pirfenidone in China,[3] and
later manufacture approval in ***3 under the trade name of
Etuary.[4]
In ***4 it was approved in Mxico under the name KitosCell LP,
indicated for pulmonary fibrosis and liver fibrosis.[5] There is
also a topical form created for the treatment of abnormal wound
healing processes
| 国家: | China |
| 型号: | Pirfenidone (INN, BAN) |
| 离岸价格: | 获取最新报价 |
| 位置: | - |
| 最小订单价格: | - |
| 最小订单: | - |
| 包装细节: | - |
| 交货时间: | - |
| 供应能力: | - |
| 付款方式: | - |
| 產品組 : | - |
